Answers are grounded in this paper and cite their sources.
Validation reveals that an oxidative phosphorylation gene signature can stratify LUSC patients by risk, indicating potential for personalized therapies.
We developed and validated a novel OXPHOS-based gene signature that effectively stratifies LUSC patients by risk. This signature highlights the clinical relevance of OXPHOS in LUSC prognosis and may guide personalized therapeutic strategies targeting metabolic vulnerabilities. Study limitations include its retrospective design and lack of experimental validation.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: